Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART
Table 10
Qualitative comparison of the results of the ISS T-002 Clinical Trial and the ISS OBS T-002 Observational Study up to 48 weeks of follow-up: activation markers, T-regs, cell viability and lymphocyte phenotype.